Sarepta is facing a number of issues currently, including platform-level safety concerns, management credibility issues, etc.

After deaths and FDA setbacks, Sarepta abandoned LGMD gene therapy, leaving families desperate and patients without ...

Sarepta Therapeutics has provided additional safety data on its gene therapy Elevidys as a Duchenne muscular dystrophy ...

Citi said on Wednesday that the U.S. Food and Drug Administration may take a “more comprehensive look” at the level of ...

Sarepta Therapeutics Inc. landed a deal with investors to restructure around $700 million of debt, giving the company a ...

The debt refinancing follows the firm's recent trouble with the FDA and efforts to refocus its pipeline priorities, preserve resources, and meet financial obligations.

Kriya is advancing a host of gene therapies for a wide variety of chronic diseases, including geographic atrophy, trigeminal ...

A refinancing deal will delay the maturity of $700 million in debt until 2030, allowing the company to “fully fund” its ...

Gene therapy biotech Kriya Therapeutics has secured $313 million in a new series fundraise. | Gene therapy biotech Kriya ...

The drug, based on Nobel Prize-winning gene-editing technology CRISPR-Cas9, reaches the liver cells and splices out the ...

Certain Sarepta Therapeutics Inc. insiders were accused in a stockholder lawsuit of reaping a combined $6.2 million selling ...

The FDA’s shift on Elevidys sends a message: boldness, scientific rigor and urgency are essential in confronting rare ...